经过长时间连续的皮下达西格卢卡贡给药后发生的消亡性迁移性红疹:一种罕见的皮肤学不良事件
Endocrinology, diabetes & metabolism case reports
|April 29, 2025
概括
在新生儿的先天性高胰岛素症 (CHI) 中,长期使用达西葡萄糖导致了严重的副作用,如死亡性迁移性红疹 (NME) 和营养不良. 停药改善了患者的情况.
科学领域:
- 内分泌学 在内分泌学.
- 新生儿科学 新生儿科学
- 皮肤病学 皮肤病学
背景情况:
- 先天性高胰岛素症 (CHI) 带来了复杂的管理挑战,治疗选择有限.
- 达西格卢加是一种合成葡萄糖类,为耐火性CHI病例提供了一种新的治疗途径.
研究的目的:
- 报告一个罕见的长期连续皮下达西格卢卡贡给新生儿的罕见病例.
- 为了突出与这种治疗方案相关的潜在严重不良影响.
主要方法:
- 一个患有CHI的新生儿的病例报告,该新生儿接受了连续的皮下达西格卢卡贡治疗.
- 监测血糖控制,皮肤病状况和营养参数.
- 评估dasiglucagon停止和随后的干预措施后患者的结果.
主要成果:
- 最初的血糖稳定是通过dasiglucagon实现的.
- 患者患上了死亡性迁移性红疹 (NME),营养不良,营养缺乏和败血症.
- 停用达西格卢卡贡导致皮肤和营养状况明显改善.
- 亚总胰腺切除术最终需要进行血糖控制.
结论:
- 长时间的连续皮下达西格卢加治疗可能会导致严重的不良反应,包括NME和营养不足.
- 密切监测皮肤,营养和传染性并发症在CHI的达西格卢卡贡治疗期间至关重要.
- 多学科的护理是管理CHI患者在达西格卢卡贡的管理,平衡血糖控制与警的副作用管理必不可少的.
相关概念视频
Hypoglycemia and Glucagon
142
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
142
Glucagon-like Receptor Agonists
270
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
270
Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127
Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111
Diabetes: Symptoms, Diagnosis, and Complications
486
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
486
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K


